Drug intelligence / Profile preview

MIC1930

Development stage: Preclinical
Lead developer: Micar Innovation
Modality: Small Molecules

Overview

MIC1930 is a preclinical-stage small molecule therapeutic candidate developed by Micar Innovation. It is being investigated for the treatment of viral respiratory infections, specifically COVID-19 and influenza. As of the current pipeline status, the specific molecular target of MIC1930 has not been disclosed by the developer. The drug is part of a broader portfolio of wholly-owned small molecules generated by Micar Innovation's drug discovery platform, which focuses on addressing unmet medical needs in infectious diseases and other therapeutic areas.

Beyond the preview

Go deeper on MIC1930.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIC1930.

Explore the full profile